PD-L1 Positive Non-small Cell Lung Cancer
1 clinical trials · Condition
◉ Watch PD-L1 Positive Non-small Cell Lung Cancer
| Record | Firm | Date |
|---|---|---|
| Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) (NCT04203485) | Jiangsu HengRui Medicine Co., Ltd. | 2020-06-15 |
Track PD-L1 Positive Non-small Cell Lung Cancer automatically
Every clearance here is in the API, with alerts when new ones post.